Background-Breast cancer is the most common cancer diagnosed among Latinas in the United States and the leading cause of cancer-related death among this population. Latinas tend to be diagnosed at a later stage and have worse prognostic features than their non-Hispanic white counterparts. Genetic and genomic factors may contribute to observed breast cancer health disparities in Latinas.
cancer residing in California, Arizona, and Texas. 22 Prevalence estimates of carrying a BRCA mutation for this US Latina group ranged from 0.7% to 42% and varied based on whether cases were selected or unselected for family history or clinical characteristics (eg, affected vs unaffected, age at diagnosis), cancer site (eg, breast, ovarian), and type of testing (eg, inclusion of large rearrangement testing). 22 In the cohorts of unselected patients with breast cancer, the BRCA mutation prevalence was 1.2% to 4.9%, which was consistent with expected rates. 22 BRCA mutations have also been documented in all residents of Latin American countries where these genes have been studied, including Argentina, Brazil, Chile, Colombia, Costa Rica, Cuba, Mexico, Peru, Puerto Rico, Uruguay, and Venezuela. Most studies have focused on the spectrum of BRCA mutations. 22, 55 In a review of BRCA1 and BRCA2 mutations in persons living in Latin America and the Caribbean, 36% of the 33 studies primarily focused on Mexican or Mexican American patients. 22 Of the Mexican study population, the mutation prevalence was between 4.3% and 23.0%. 22 For other Latina subethnic groups, the mutation prevalence estimates of each country studied were: Colombia (1.2%-15.6%; 2 studies), Costa Rica (4.5%; 1 study), Cuba (2.6%; 1 study), Peru (4.9%; 1 study), Uruguay (17%; 1 study), and Venezuela (17.2%; 1 study). 22 These studies provide insight into areas of future research of BRCA mutation distribution and frequency based on country of origin, the role of specific founder mutations, the contribution of large genomic rearrangements to the spectrum of mutations across various Latina subethnic groups, and the consideration of other non-BRCA genes that increase the risk of breast cancer.
Although recurrent mutations were identified within most studies, the specific mutation varied by study and country. 22 BRCA1 185delAG has also been documented in Latinas across Latin America and the United States. 43, [45] [46] [47] 50, [56] [57] [58] One of the 3 Jewish founder mutations, BRCA1 185delAG is estimated to have arisen about 800 years ago or earlier and is believed to have been introduced into Latin America about 650 years ago. 59 When this mutation is identified in Latinos, haplotype analysis supports that this mutation is of the same origin as the Jewish founder mutation, rather than a separate genetic event. 60, 61 Pooled mutation estimates performed by Porchia et al 55 found that BRCA1 185delAG is the second most prevalent BRCA1 mutation and its frequency is not significantly different between Mexico and other Latin American countries (P = .70). However, it is worth noting that not all Central and South American countries were represented in their analysis. 55 The most common BRCA1 mutation in the same meta-analysis was deletion of exons 9 to 12. 55 This mutation is estimated to have originated nearly 1,500 years ago near Puebla Mexico. 48, 58 However, to date, it has been reported in Mexicans and Mexican Americans alone. 22, 35, 55, 61, 62 The contribution of large genomic rearrangements to BRCA1 in Latin American patients was evaluated in a study of US Latinas and described the prevalence of rearrangements by racial and ethnic groups. 63 Large rearrangements were significantly more common in individuals who reported Latin American ancestry, and the prevalence of rearrangements was two-fold higher than in the overall population tested. 63 This laboratorybased cohort extracted ethnicity data from genetic testing request forms; therefore, no data about subethnicity was available. 63 However, the 2 most frequent BRCA1 rearrangements reflecting the underlying US Latino population in whom the majority is of Mexican ancestry. 63 In a Puerto Rican study, BRCA1 deletion of exons 1 to 2 was seen in nearly 20% of study patients positive for BRCA1. 52 Because Puerto Ricans represent the second largest US Latino group after those of Mexican ancestry, these findings support utilizing an assay that includes large rearrangements when testing Latinos. 52 The study results also highlight the importance of understanding more granular aspects of ethnicity, such as country of origin, to ensure that all mutations that contribute significantly are captured.
Dutil et al 22 noted that most Latin American studies they reviewed identified a higher proportion of BRCA1 than BRCA2 mutations, a finding similar to reports in other populations. However, studies from 4 different countries (Costa Rica, 40 Cuba, 38 Puerto Rico, 52 Uruguay 64 ) reported more BRCA2 mutations than those in BRCA1. While these studies may have been limited by sample size and the mutation-detection strategies and technologies, 38, 40, 52, 64 this finding has been also reported in a single US-based clinical site and may warrant further exploration. 68 The meta-analysis performed by Porchia et al 55 identified recurrent BRCA2 mutations across all studies with the following pooled prevalence: H372N (0.88%; 95% confidence interval [CI], 0.24-1.92), E49X (0.38%; 95% CI, 0.13-0.75), and 3492insT (0.32%; 95% CI, 0.24-0.53). BRCA2 3492insT has been identified in different regions of Spain with a frequency as high as 2.08%. [65] [66] [67] [68] [69] [70] [71] Although it is possible that this mutation was introduced in Latin America by the Spaniards, no haplotype studies of this specific mutation were identified to confirm a shared ancestry rather than a separate mutational event. 52 BRCA1 and BRCA2 account for the majority of hereditary breast cancer, but other highand moderate-risk genes also predispose individuals to breast cancer, including TP53, PTEN, CDH1, STK11, CHEK2, PALB2, ATM, and others. 25, 29, 30, [72] [73] [74] [75] [76] [77] [78] [79] [80] Limited studies have been performed of non-BRCA genes in Latina breast cancer cohorts, leaving much to be learned about the prevalence and spectrum of mutations in these genes among Latinas with breast cancer (Table 1) . 25, 29, 30, [72] [73] [74] [75] [76] [77] [78] [79] [80] One exception is the Brazilian founder mutation in TP53, R337H. Mutations in TP53 cause Li-Fraumeni syndrome, which is associated with an elevated risk for a wide spectrum of cancers, including adrenal cortical carcinoma, soft-tissue and bone sarcomas, brain tumors, and breast cancer. [81] [82] [83] The overall contribution of TP53 mutations to breast cancer is estimated to be less than 1%, unless selecting for early-onset breast cancer. 84, 85 In studies of women diagnosed with breast cancer at or before the age of 30 or 35 years, 5% to 8% had TP53 mutations. [86] [87] [88] [89] TP53 R337H was first identified in individuals with childhood adrenal cortical carcinomas living in southern Brazil. 90 This mutation occurs in 2.4% to 8.6% of Brazilian women with breast cancer. 72, 73, 90, 91 In a large study, which included 403 patients with breast cancer diagnosed at 45 years or younger, 12.1% carried the TP53 R337H mutation. Although the mutation was significantly more frequent in younger patients compared with those diagnosed at or above age 55 years (P < .001), 5.1% of the older group carried the mutation. 73 To date, no other populations have been identified in whom TP53 makes such a significant contribution to breast cancer. The prevalence of this mutation in southern Brazil has been estimated be approximately 0.3%. 92, 93 Additional haplotype analyses support the hypothesis that this recurrent mutation is a founder mutation from a shared ancestor. 73, 94 Historically, the genetic assessment for hereditary breast cancer involved the formation of a differential diagnosis followed by a syndrome-by-syndrome evaluation through the sequential testing of genes. However, the rapid integration of next-generation sequencing has enabled simultaneous testing of multiple inherited cancer genes, thereby expanding the use of multigene panels in clinical testing at a reduced cost. 95 This expansion is reflected in the emerging body of literature on breast cancer focused on multigene panel findings from the research, clinical, and laboratory settings. [96] [97] [98] [99] [100] [101] [102] [103] [104] These literature cohorts are predominantly non-Hispanic whites, with Latinas representing less than 1.0% to 7.4% of study participants [96] [97] [98] [99] [101] [102] [103] -thus highlighting another area where future research is needed. One study of 475 patients undergoing multigene panel testing included 228 Latino patients (47.6% of study population), and it reported that the likelihood of detecting a deleterious mutation was no different among the ethnic and racial groups represented. 102 Of the patients with breast cancer (n = 197), 14.8% (n = 28) carried mutations, and, as expected, BRCA1 and BRCA2 were the most commonly mutated genes; however, 16 mutations were identified in other genes (CDH1 = 4, CHEK2 = 3, MUTYH = 3, PALB2 = 2, TP53 = 1, RAD50 = 1, RAD51D = 1, BARD1 = 1). 102 Of note, the likelihood of identifying more than 1 variant of uncertain significance in Latinos was significantly higher than that of non-Hispanics whites. 105 Thus, a need exists for further research to better classify rare variants, especially given the under-representation of Latinos in laboratory and research databases.
Genetic Counseling and Testing

Patient-and Health Care-Related Factors
An important step toward understanding the role of BRCA and other high-and moderaterisk breast cancer genes in Latinas is to increase the number of individuals who receive genetic counseling and subsequently elect to undergo testing. However, growing evidence identifies disparities in awareness of and access to genetic counseling among Latinas compared with non-Hispanic white women. Data from health interview surveys from 2000, 2005, and 2010 show that Latinas had the lowest level of awareness about genetic testing for inherited cancer risk than all of the other US racial ethnic groups. [106] [107] [108] Using telephone surveys, Gammon et al 109 studied 63 Latinas and 84 non-Hispanic whites at increased risk for carrying a BRCA1 or BRCA2 mutation, examining their awareness, cognitions, and psychosocial needs related to genetic counseling and testing. Among those who had not previously undergone genetic counseling (53 of the 120), Latinas were more unaware than their white counterparts of the availability of testing (56.9% vs 34.8%, respectively). 109 Vadaparampil et al 110 reported on a sample of Latinas with a personal or family history of breast cancer, all of whom reported an awareness of genetic risk for breast cancer (ie, family history). However, none of the Latinas had a clear understanding of what genetic testing was and had not received physician referral for genetic testing. 110 Findings did differ based on country of origin -an important are to consider in future work, given the diversity of Hispanic populations across the United States. 110 In another report, Kaplan et al 111 reported differences in awareness of genetic testing by race and ethnicity such that 19.4% of Latinas had heard of genetic testing compared with 59.4% of whites, 26.1% of Asian Americans, and 31.0% of black women.
In a study of more than 2,400 patients completing a family cancer history form, Mays et al 112 found that, overall, despite low levels of initial awareness, 65 patients (2.7%) met criteria for cancer risk assessment; of those, 72.3% expressed interest in receiving genetic counseling. Furthermore, no differences in interest in genetic services were reported across all racial and ethnic groups. 112 Among 1,536 women with nonmetastatic breast cancer, Jagsi et al 113 found that Latinas had a greater desire for genetic counseling than other groups (58.8% of Spanish-speaking Latinas; 36.7% of English-speaking Latinas; 27.1% of non-Hispanic whites; and 28.1% of blacks). In addition, Lagos et al 114 examined social, cognitive, and cultural variables among Latinas prior to an appointment for genetic counseling. Fifty low-income, underserved Latinas completed the assessment, and the results demonstrated their readiness (having the necessary skills for the genetic-counseling process), low fatalism, and high rate of self-efficacy, and social support. 114 However, this study was conducted in women who showed up to their genetic counseling appointments, thus representing a unique group of women. 114 Vadaparampil et al 115 studied a group of Puerto Rican women (living in Puerto Rico or central Florida) with a family or personal history of breast cancer and found that the vast majority of participants said they would undergo genetic testing within the next 6 months if it was available. Barriers included the cost of testing and potential pain.
Uptake of Services
Given lower levels of patient awareness, physician recommendations may provide a critical approach to increasing utilization of genetic counseling and testing for hereditary risk of breast cancer. However, available studies 113, 116, 117 suggest a missed clinical opportunity, because both English-and Spanish-speaking Latina survivors of breast cancer were more likely to have unmet needs for discussion with a health care professional about cancer genetic testing than their non-Hispanic white counterparts. For example, Jagsi et al 113 reports that minority patients were the most likely to express an unmet need for a discussion about genetic testing, although they also showed a strong desire for such testing.
Preliminary studies support the uptake of genetic counseling when services are offered. [118] [119] [120] [121] One study of predominantly Latina patients (71.4%) offered genetic counseling at the safety-net hospital found that 88.0% kept their appointments. 118 Another study of women (69.6% were Latinas) seen in the safety-net hospital setting reported that 96.4% of them underwent BRCA testing when it was recommended to them. 119 
Once
Overall, these studies have focused on the delivery of cancer genetics services to majority Latina cohorts, demonstrating that genetic counseling and testing is likely well-received by Latinas with breast cancer; however, these studies were all conducted in safety-net hospitals or in community, low-resource settings and were aimed at the provision of service to lowincome, uninsured patients. [118] [119] [120] [121] Although Latinas continue to be disproportionally uninsured or underinsured, these study findings might not generalize to other health care settings. Thus, further studies are needed across various clinical settings and in a wider representation of Latinas with breast cancer to better understand the utilization of genetic testing as well as the barriers for referrals.
Common Genetic Polymorphisms and Risk of Breast Cancer
Genome-Wide Association Studies
Progress in the discovery of germline genetic polymorphisms associated with breast cancer risk changed pace when technological advances in genotyping made it possible to characterize genome-wide genetic variation at a relatively low cost. 122 In 2007, the first breast cancer genome-wide association studies were published, and they reported a handful of single nucleotide polymorphisms (SNPs) associated with a modest increase in risk. [123] [124] [125] Since then, more than 100 common variants that either increase risk for or are protective against developing breast cancer have been discovered and, including replication efforts, data from more than 120,000 women have been analyzed. A small proportion of samples included in these major initiatives are from minority populations in the United States (eg, Latinas, African Americans) and the first results of genome-wide association studies of Latinas with breast cancer were published in 2014. 147 This latter study represents important but limited progress, considering that the sample size was one-tenth of that available for genome-wide association studies involving women of European origin. [123] [124] [125] 147 Until the first genome-wide association studies of breast cancer in women of European origin were published, the search for risk predisposing genetic variants was focused on finding polymorphisms within genes that, for known or hypothesized involvement in the biology of the disease, were likely to contribute to breast cancer risk. [123] [124] [125] These studies in US Latinas or Latin American women typically consisted of the replication of previously associated polymorphisms reported in Europeans, with few of these studies looking for variation in samples of Latinas before further testing specific polymorphisms for associations in larger samples. 148, 149 Compared with the hundreds of genome-wide association studies in non-Hispanic white women, we identified 13 case-control studies or cohorts that include US Latina or Latin American women. [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] These studies include populations of women of no more than 100 and up to approximately 5,000 women of Latin American origin; combined, the study populations tally approximately 5,000 Latina women with breast cancer and 11,000 Latina healthy controls. [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] 
Candidate Gene or Pathway Studies
Multiple breast cancer-association studies of candidate genes or pathways have been reported for US Latina and Latin American women during the last 20 years. Genes or pathways studied have included those related to hormone metabolism, hormone receptors, and hormone coactivators or supressors, 148, [164] [165] [166] [167] [168] [169] growth factors, 149, [170] [171] [172] [173] [174] [175] [176] matrix metalloproteinases, 177, 178 inflammation and energy balance, 158,179-184 metabolism of xenobiotic compounds and oxidative stress, 159, [185] [186] [187] [188] DNA repair, 160, 161, 163, 189 and angiogenesis. 190 Results reported in these publications should be interpreted with caution, given that approximately 60% of the candidate gene analyses included in our report did not adjust for genetic ancestry, which is a known confounder in genetic association studies in admixed populations. 191, 192 In addition, no associations in candidate gene or pathways studies, nor any of the interactions with risk factors, genetic ancestry, or tumor characteristics, have been replicated in independent samples of Latinas.
Replication of Identified Single Nucleotide Polymorphisms
Few studies have included Latinas and tested the association between SNPs discovered in genome-wide association studies of breast cancer conducted in samples of European or Asian women. [193] [194] [195] [196] [197] [198] The first study genotyped previously reported SNPs in the 2q35 region and FGFR2, TOX3, and MAP3K1, reported statistically significant replications for the polymorphisms in FGFR2 and 2q35. 193 Two different studies published the results of analyses conducted in the same sample of high-risk families from Chile and healthy controls, testing associations between previously reported variants in FGFR2, MAP3K1, and TOX3 and the 2q35 and 8q24 regions and breast cancer risk. 197, 198 They replicated the associations for FGFR2, MAP3K1, TOX3, and 2q35 but not for 8q24. 197, 198 An analysis conducted in a pooled sample of Latina cases and controls from the Four-Corners study, San Francisco Bay Area Breast Cancer Study, and a study in Mexico, investigated the association between 10 identified polymorphisms in genome-wide association studies (in region 2q35 and in or near RELN, MRPS30, RNF146, FGFR2, TOX3, LSP1, TLR1, MAP3K1, RAD51L1) and breast cancer risk. 195 They replicated associations for the polymorphisms in RELN, FGFR2, TOX3, and TLR1 and 2q35 and found heterogeneity by ancestry for the RELN, 2q35, and TLR1 SNPs. 195 A follow-up study reported that the heterogeneity by ancestry for the 2q35 polymorphism was likely due to the association between genetic ancestry, use of hormone therapy, and breastfeeding. 194 Another analysis of the FGFR2 polymorphism in the Mexican study reported an interaction between the FGFR2 polymorphism and alcohol intake. 196 The first genome-wide association study of breast cancer in US Latinas also replicated previous associations, with most of the SNPs being concordant in terms of direction and magnitude of association with those reported in European or Asian populations. 147 Twenty-three of the 83 variants tested had probably values below .05. 147
Ancestry
Admixture mapping leverages the demographical history of admixed populations to find genomic regions that may carry trait-associated variants. [199] [200] [201] [202] [203] [204] [205] [206] [207] An admixed population results from the combination of 2 or more ancestral groups. 200 The principle of admixture 
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Author Manuscript mapping is to identify genomic regions in which cases share more of the same genetic ancestry than either population-based controls (case-control analysis) or compared with the average ancestry of the rest of the genome among cases (case-only analysis). 202 This approach has identified risk variants or risk regions for multiple complex traits, including obesity, hypertension, and cancer. 199, 201, [203] [204] [205] [206] [207] The incidence of breast cancer varies across different racial and ethnic groups in the United States, and Latinas have lower incidence rates than non-Hispanic whites but higher rates than American Indian women. 208 Genetic ancestry has also been associated with breast cancer risk in US Latinas and Mexican women after adjusting for non-genetic risk factors, suggesting that a genetic component could be responsible for the difference in risk. 158, 209, 210 An admixture mapping study in Latinas reported a statistically significant association between a region in the long arm of chromosome 6 (6q25) near ESR1 and risk of breast cancer and a suggestive association on chromosome 11. 211 Higher Indigenous American ancestry at chromosome 6q25 was associated with lower risk of breast cancer. 211 This finding was concordant with the previous reports of lower rates of risk of breast cancer among Latinas with high American Indian ancestry compared with women with high European ancestry after adjusting for possible risk factors such as socioeconomic status, number of full-term pregnancies, and breast feeding. [209] [210] [211] One included a discovery phase and replication in 3 additional studies. 147 The study reported genome-wide results that were statistically significant for 2 linked SNPs 56kb upstream of ESR1 (rs140068132 and rs147157845). 147 These SNPs have a frequency of between 5% and 23% in Latin American populations and are absent in most all other groups. 147 The minor allele was protective, with an associated odds ratio (OR) of 0.60 (95% CI, 0.53-0.67) per allele and was more protective for estrogen receptor (ER)-negative disease than for ER-positive disease (OR for ER-negative disease 0.34; 95% CI, 0.21-0.54). 147
Treatment Tumor Genomics
A growing body of evidence suggests differences in the tumor biology of breast carcinoma across various races and ethnicities. Several studies have evaluated the prevalence of phenotypic subtypes of breast cancer in Latinas compared with other population groups. [212] [213] [214] [215] [216] [217] [218] Most data have shown a higher proportion of hormone receptor-negative disease types among Latinas when compared with non-Hispanic whites ( Table 2) . 3, [212] [213] [214] [215] [216] However, those results have not always been concordant, and the differences seen across these studies could represent small sample sizes, patient age, or unadjusted rates for genetic ancestry. Although studies based on data from the California Cancer Registry indicated a higher proportion of triple-negative tumors, 217 this finding was not confirmed in a Colorado study. 212 In a retrospective study performed in Brazil, patients in the southern regions with a higher percentage of European ancestry and higher socioeconomic status presented with the highest proportion of luminal tumors, whereas the more aggressive subtypes were seen in the northern parts of Brazil, an area with a higher African ancestral influence. 218 Lynce et al. 
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Approximately 15% of breast cancer types overexpress erb-b2 receptor tyrosine kinase 2 (ERBB2; also referred to as epidermal growth factor receptor 2 [HER2 or HER2/neu]) protein. 219 High levels of HER2 expression identify those women who benefit from treatment with HER2-targeted agents, which have been shown to increase survival in the adjuvant and metastatic settings. 220, 221 Most studies with HER2-targeted therapies have enrolled majority populations of non-Hispanic whites, although consistent evidence demonstrates that a higher proportion of HER2-positive tumors exist among Latinas, even after adjusting for other tumor characteristics (eg, grade, stage, ER status) and breast cancer risk factors (eg, number of children, alcohol consumption). 212 Further tumor characterization has been made possible due to advances in molecular tumor profiling. Oncotype DX (Genomic Health, Redwood City, CA) is a 21-gene breast cancer assay -known as a recurrence score -that provides prognostic and predictive information regarding the benefits of adjuvant chemotherapy in patients with ER-positive tumors. Use of Oncotype DX is part of several guidelines from professional medical organizations, including the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the European Society for Medical Oncology. [222] [223] [224] The characteristics of this assay and the impact of its results on treatment decisions among Latinas with breast cancer are lacking in the medical literature. Kalinsky et al 225 studied 74 Latinas and 145 non-Hispanic white women matched for age, disease stage, and nodal status, and they observed no differences in the overall recurrence score, ER or progesterone receptor status, or HER2 expression by Oncotype DX. However, Latinas had a higher expression of CCNB1 and AURKA, 2 genes that are part of the proliferation score and heavily weighted in the calculation of the recurrence score.
Multiple trials whose study populations were mostly comprised of non-Hispanic white women have shown that use of Oncotype DX affects treatment recommendations and leads to an increase in physician and patient confidence in treatment decisions. [226] [227] [228] [229] A small study of 96 patients with breast cancer treated in Mexico showed that use of the Oncotype DX changed treatment decisions for 32% of patients, a finding suggesting that its use has a meaningful impact on recommendations for adjuvant treatment. 230 Results from costeffectiveness analyses indicated that use of the Oncotype DX assay was projected to improve rates of life expectancy when compared with the current standard of care. 231
Pharmacogenomics
Several factors cause variations in the individual response to drugs, including age, body mass index, diet, and genetic variation. [232] [233] [234] SNPs in genes related to drug-metabolizing enzymes have been recognized as important determinants of variability to drug response. 235 Most studies have not been sufficiently powered to determine whether specific chemotherapy agents used to treat breast cancer have different rates of effectiveness and toxicities based on race or ethnicity. 236 However, differences in the metabolism of endocrine therapies have been well documented according to race and ethnicity. [237] [238] [239] [240] In a study that evaluated clinical data and blood samples from patients with breast cancer undergoing adjuvant tamoxifen therapy, mostly non-Hispanic white women (68%) and Latinas (26%) had significantly higher serum levels of tamoxifen and 4-hydroxytamoxifen, 
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Author Manuscript one of tamoxifen metabolites (P = .02 and P = .007, respectively). 237 In 2 other studies, genetic polymorphisms in CYP2D6 associated with lower plasma concentrations of the active metabolites of tamoxifen were described in Mexican, Puerto Rican, and Spanish patients. 238, 239 A higher prevalence of this poor metabolizer phenotype has also been observed in non-Hispanic whites. 240 In an attempt to clarify whether CYP2D6 allele status influences outcomes from tamoxifen, investigators assessed data from 2 large prospective trials and found that CYP2D6 allele status did not predict clinical benefit of adjuvant tamoxifen in terms of risk of recurrence. 241, 242 Therefore, changes in treatment decisions based on CYP2D6 allele status alone are not recommended. Differences in the incidence of polymorphisms of the aromatase gene among different ethnic groups have also been reported and could potentially lead to different outcomes and toxicities among populations. 243 One trial evaluated the benefit of extended hormonal therapy with an aromatase inhibitor after 5 years of tamoxifen treatment in non-Hispanic whites (n = 4,708) and minority women (n = 352; 1.5% were Latinas). 244 In general, the researchers found that, compared with non-Hispanic whites, minorities had fewer associated toxicities and no definitive survival benefit with aromatase inhibitors. 244 However, these results should be cautiously interpreted, because the minorities participants were less adherent to hormonal therapy and the study was not powered to detect survival benefit in the subgroups. 244
Conclusions
Several genetic and genomic factors are related to the health disparities of breast cancer in Latinas. Increasing our knowledge about the contribution of high-and moderate-penetrance mutations to the risk of breast cancer among Latinas overall and for subgroups based on country of origin is an important priority. Although genetic counseling and testing for inherited susceptibility to breast cancer has been clinically available for nearly 20 years, disparities in awareness, referral to services, and access persist. Therefore, interventions to address barriers related to low levels of awareness and lacking physician referrals are critical. [106] [107] [108] [109] [110] [111] Even though multiple candidate gene studies have been conducted in this population, only identified variants in genome-wide association studies have been systematically replicated. Much larger sample sizes will be required if we expect to discover similar results in Latinas as would be identified for the European genome in view of their Indigenous American component. We cannot assume that overlapping variants alone between different ancestral genomes will be associated with rate of risk, so our efforts should be focused on reducing research disparities by expanding available resources to include large cohorts and casecontrol studies of diverse populations in and outside the United States.
Latinas remain systematically underrepresented in pharmacogenomics studies and the current studies were not powered to detect outcome differences. They are also underrepresented in clinical treatment trials and other patient-reported outcomes research. Future research should draw from the few models of success in prior studies that have recruited sufficient numbers of Latinos. [245] [246] [247] [248] Lessons can also be learned from successful examples of recruiting other racial and ethnic minority patients who have survived breast cancer. 249 Elements that appear to bolster success include partnership with community-based organizations that provide services to Latinas and the provision of languageconcurrent clinical care. [250] [251] [252] The heterogeneity of the US Latina population must also be considered, because different cultural influences, levels of awareness of, and interest in genetic and genomic services appear to vary by country of origin. 110 An urgent need exists to ensure that existing genomic research considers the unique needs of this Latina population. As the US population continues to diversify with up to one-third identifying as Hispanics by 2060, 1 extending genetic and genomic research into this underserved and understudied population will be critical. By understanding the risk of breast cancer among diverse populations, we will be better positioned to make advancements in the number of women diagnosed at earlier stages, identify more effective and less toxic treatment regimens, and increase rates of survival. Meeting these goals will contribute to reducing the current health disparities in these patients with breast cancer. 
